Company: INVUP
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001193
Chunk: 410

Company: Investview, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9A
Chunk 410
---
 of the Company’s current assets, would not have a material adverse effect
upon the Company’s long-term liquidity, however, could have a material adverse effect upon the Company’s net earnings in
the period incurred.

Joseph
Cammarata served as an officer and director of the Company from December 2019 through his termination for cause on or about December
7, 2021. Mr. Cammarata was terminated following the announcement of civil and criminal charges filed against him in connection with his
involvement with a class action claims aggregator unrelated to the Company. The Company was unaware of these outside business interests.
Based on public reporting of the matter, the Company believes that Mr. Cammarata was convicted of certain of these criminal charges and
is presently incarcerated.

Prior
to his termination, Mr. Cammarata and the Company engaged in certain transactions as described below:

We
issued a promissory note to Mr. Cammarata, which, following certain modifications, on or about March 30, 2021, was restated in the principal
amount of $1,550,000 (the “Cammarata Note”). Although not originally convertible, as per the March 30, 2021, amendment, the
Cammarata Note became convertible at $0.02 per share, Thereafter, effective September 21, 2021, and following another modification, the
conversion price under the Cammarata Note was reduced to $0.008 per share. During February 2022, we provided 30 days’ notice of
our intent to retire and repay the Cammarata Note in cash. Having not timely received a properly executed conversion notice within the
proscribed period and citing certain breaches of Mr. Cammarata’s fiduciary duty to us, as well as damages incurred by us arising
from Mr. Cammarata’s then ongoing legal proceedings, on or about March 31, 2022, we tendered to Mr. Cammarata cash payment in full
for the Cammarata Note. As of the date of this Report, Mr. Cammarata has not accepted our tender of the cash payment, and through his
then counsel, has asserted his entitlement to exercise his right to convert the Cammarata Note into our common shares. Although we believe
that our cash tender was appropriate under the terms of the Cammarata Note and our claims for damages by Mr. Cammarata have merit, if
Mr. Cammarata elects to